Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer

NCT03999515 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03999515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03999515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
April 27, 2020
Completion date
June 6, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, double-negative prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8